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Abstract
Background: Tripartite motif (TRIM) proteins constitute a family of proteins that share a conserved tripartite architecture.
The recent discovery of the anti-HIV activity of TRIM5a in primate cells has stimulated much interest in the potential role of
TRIM proteins in antiviral activities and innate immunity.
Principal Findings: To test if TRIM genes are up-regulated during antiviral immune responses, we performed a systematic
analysis of TRIM gene expression in human primary lymphocytes and monocyte-derived macrophages in response to
interferons (IFNs, type I and II) or following FccR-mediated activation of macrophages. We found that 27 of the 72 human
TRIM genes are sensitive to IFN. Our analysis identifies 9 additional TRIM genes that are up-regulated by IFNs, among which
only 3 have previously been found to display an antiviral activity. Also, we found 2 TRIM proteins, TRIM9 and 54, to be
specifically up-regulated in FccR-activated macrophages.
Conclusions: Our results present the first comprehensive TRIM gene expression analysis in primary human immune cells,
and suggest the involvement of additional TRIM proteins in regulating host antiviral activities.
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Introduction
Tripartite motif (TRIM) proteins constitute a protein family
based on a conserved domain architecture (known as RBCC) that
is characterized by a RING finger domain, one or two B-box
domains, a Coiled-coil domain and a variable C-terminus [1]
(Figure 1). Despite their common domain architecture, TRIM
proteins are implicated in a variety of cellular functions, including
differentiation, apoptosis and immunity [1]. Interestingly, an
increasing number of TRIM proteins have been found to display
antiviral activities or are known to be involved in processes
associated with innate immunity [2,3]. TRIM5a is responsible for
a species-specific post-entry restriction of diverse retroviruses,
including N-MLV and HIV-1, in primate cells [4,5,6,7,8],
whereas TRIM1/MID2 also displays an anti-retroviral activity
which affects specifically N-MLV infection [8]. TRIM22, also
known as Staf50, has been shown to inhibit HIV-1 replication,
although it is still unclear at what step the block occurs [9,10,11].
TRIM28 restricts MLV LTR-driven transcription in murine
embryonic cells [12]. Furthermore, the inhibition of a wide range
of RNA and DNA viruses by TRIM19/PML has been reported
[13]. The most extensive screen performed to date showed that
several TRIM proteins, including TRIM11, TRIM31 and
TRIM62, can interfere with various stages of MLV or HIV-1
replication [14]. Finally, TRIM25 has been shown to control RIG-
I-mediated antiviral activity through its E3 ubiquitin ligase activity
[15].
In one approach aimed to identify members of TRIM family
with potential antiviral activity, Harmit Malik and colleagues
sought TRIM proteins that have been under positive selection
throughout evolution suggesting that they directly interface with
ever evolving pathogens. Among these proteins are TRIM5 and
TRIM22 [16,17]. In an alternative approach, the identification of
TRIM proteins up-regulated in response to interferons (IFNs) may
pinpoint TRIM proteins with antiviral activities. IFNs are the
main mediators of innate immunity against viral infection, by up-
regulating the expression of many antiviral effectors within cells.
Three classes of IFN have been identified, designated types I to III,
and classified on the basis of the receptor complex they signal
through, and their biological activities. Type I IFNs are a vast
group of cytokines produced by most cells upon viral infection and
trigger a signaling cascade that leads to the induction of many
genes that control virus replication and spreading. Type I IFNs
consist of multiple alpha interferon (IFN-a) subtypes and only one
isoform of IFN-b, IFN-v, IFN-e or IFN-k. Type II IFN only
comprises one member, IFN-c, and is produced exclusively by
subsets of activated T lymphocytes and NK cells. The more
recently described type III IFNs include three IFN-l gene
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they are known to regulate the antiviral response and have been
proposed to be the ancestral type I IFNs [18,19].
Strikingly, most of the TRIM proteins implicated in antiviral
response, including TRIM5 [20,21,22], TRIM19/PML
[23,24,25], TRIM20/MEFV [26], TRIM21/Ro52 [27,28],
TRIM22 [9,10], TRIM25 [29,30] and TRIM34 [31] have also
been found to be up-regulated by IFNs. In addition, microarrays
have contributed to information about the gene expression of
TRIM proteins. For example, in the human fibrosarcoma cell line
Figure 1. Human TRIM proteins. Classification of human TRIM proteins based on the nature of their C-terminal domains(s) as defined by Short
and Cox [54] and modified by Ozato et al. [3]. The TRIM protein family is composed of 11 sub-families, from C-I to C-XI, whereas some TRIM proteins
remain unclassified (UC), since they do not have a RING finger domain as ‘‘true’’ TRIM proteins. NHL, NHL repeats; COS, COS box motif; FN3,
fibronectin type III motif; PHD, plant homeodomain; BROMO, bromodomain; MATH, meprin and TRAF homology domain; TM, transmembrane
domain; AR, acid-rich region.
doi:10.1371/journal.pone.0004894.g001
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autoantigen) were found to be induced by both type I and II
IFNs, whereas TRIM22 (Staf50) expression was only up-regulated
by type I (a and b) IFN [32]. Similarly, TRIM19/PML, 21
(SSA1), 22 and 25 (ZNF147) were found to be up-regulated by
pegylated interferon-alpha2b in human peripheral blood cells
[33]. In murine cells, a recent study of gene expression of a
significant proportion of TRIM proteins and an additional
microarray study provided some insight into the expression of
this protein family in mouse [34,35]. However, no comprehensive
study has been performed thus far for the entire TRIM protein
family. Besides IFN, ITAM-coupled receptors for the Fc region of
immunoglobulins (FcRs) regulate macrophage responses to
pathogens [36]. Activating FccR signaling via ITAM motifs not
only triggers signaling pathways different from those activated by
IFNs, but FccR cross-linking by IC can negatively regulate IFN-
induced signaling [37,38]. We have shown that the aggregation of
FccR by immune complexes (IC) inhibits replication of HIV-1 and
related lentiviruses in human monocyte-derived macrophages
[39,40]. FccR-mediated restriction affects early pre-integrative
steps of HIV-1 replication and might be compatible with a
TRIM5a-like restriction mechanism [40]. No information is
available on the regulation of TRIM protein expression following
FccR engagement.
Here we report a systematic study of the expression of all TRIM
genes and their sensitivity to type I IFN, type II IFN, and FccR
signaling in human primary lymphocytes and macrophages. We
decided not to include type III IFNs in our study since, despite
binding to distinct receptors from those of type I IFNs, type III
IFNs induce antiviral activity using the same signaling pathway,
the same IFN-stimulated response elements (ISREs), and lead to
the induction of almost the same IFN-stimulated genes (ISGs) than
type I (a and b) IFNs [18,41]. We applied quantitative RT-PCR
arrays to quantify the expression of the 72 human TRIM genes in
treated or untreated cells. Although some of these genes cannot be
considered as ‘‘real’’ TRIM genes since they encode proteins that
do not contain an intact RBCC architecture, we decided to
include them in our study, as they probably derive from a common
ancestor gene.
Materials and Methods
Monocyte derived macrophages (MDM) and peripheral
blood lymphocytes (PBL)
Blood samples were obtained through the French blood bank
(Etablissement Franc ¸ais du Sang, EFS) in the setting of the EFS-
Institut Pasteur Convention. A written informed consent was
obtained from each donor to use the cells for clinical research
according to French laws. The study was approved by two IRBs,
one for EFS, as required by French law, and one for Pasteur
Institute (the Biomedical Research Committee), as required by
Pasteur Institute. Human monocytes and lymphocytes were
isolated from buffy coats of healthy seronegative donors (Centre
de Transfusion Sanguine Ile-de-France, Rungis and Ho ˆpital de la
Pitie ´-Salpe ˆtrie `re, Paris, France) using lymphocyte separation
medium (PAA laboratories GmbH, Pasching, Austria) density
gradient centrifugation and plastic adherence as previously
described [40]. Non adherent cells (PBL) were frozen in 90%
fetal calf serum (FCS) and 10% DMSO at 280uC until the
experiment of activation. Monocytes were then differentiated into
macrophages by 7 to 11 days culture in MDM medium (RPMI
1640 medium supplemented with 200 mM L-glutamine, 100 U
penicillin, 100 mg streptomycin, 10 mM HEPES, 10 mM sodium
pyruvate, 50 mM b-mercaptoethanol, 1% minimum essential
medium vitamins, and 1% nonessential amino acids) supplement-
ed with 15% of human AB serum in hydrophobic Teflon dishes
(Lumox
TM, Dominique Dutcher, Brumath, France) as previously
described [40]. Monocyte-derived-macrophages (MDM) were
then harvested, washed and resuspended in MDM medium
containing 10% heat-inactivated FCS for experiments. Purity of
MDM was assessed by flow cytometry by side and forward
scattering and immunofluorescent staining. Cells obtained by this
method are 91–95% CD14
+, and express CD64, CD32, and
CD16 FccRs.
One day before experiments, PBL were thawed and cultured in
PBL medium (RPMI 1640 medium supplemented with 200 mM
L-glutamine, 100 U penicillin, 100 mg streptomycin, 10% FCS).
PBL and MDM were seeded in 6 well plates (2610
6 PBL/well,
1610
6 MDM/well) in the presence or not of 1000 UI/ml of IFN I
(Universal type I IFN, PBL Biomedical Laboratories, New
Brunswick, USA)(Universal type I IFN is an hybrid alpha
interferon, constructed from recombinant human IFN-a A and
human IFN-a D) or IFN II (IFN-c, Peprotech EC Ltd, London,
UK). MDM stimulation with preformed immune complexes (IC)
was performed as previously described [40]. Briefly, culture plates
were coated with 0.1 mg/ml dinitrophenyl-conjugated bovine
serum albumin (DNP-BSA) by incubation for 2 hours at 37uC,
saturated with 1 mg/ml BSA in PBS, and then incubated 1 h hour
at 37uC with 30 mg/ml rabbit anti-DNP antibodies (Sigma, Saint
Louis, USA) to form ICs. All reagents used were LPS-free. After
washing of the plates with PBS, MDM were stimulated by plating
on IC-coated wells.
Eight hours after stimulation with either IFNs or IC, cells were
finally washed and frozen at 280uC in the presence of 350 mlo f
RLT buffer/well (RNeasy Mini kit, Qiagen). RNA extractions
were performed using RNeasy Mini Kit following manufacturer’s
instructions. Experiments were performed using PBL and MDM
from 3 different donors.
qRT-PCR array analysis
We designed custom RT
2 Profiler PCR arrays (SABiosciences,
Frederick, USA) in order to quantify simultaneously the expression
of 72 human TRIM genes and 14 other human genes for control.
The complete list of the 86 screened genes is shown in Table 1.
Briefly, total RNA from PBL or MDM isolated from 3 donors and
treated or not with IFN I, IFN II or IC were reverse transcribed
using the RT
2 PCR array first strand kit (SABiosciences). PCR
were performed using the RT
2 Realtime SYBR Green PCR mix
(SABiosciences) following manufacturer’s instructions on a Light-
Cycler 480 (Roche Diagnostics, Meylan, France). Data were
analyzed by the 2
2DDCt method. Briefly, threshold cycle (Ct)
values were converted to 2
2Ct in order to be proportional to the
amount of transcripts in the samples. For comparing samples
between them, 2
2DCt were calculated by normalizing the data by a
housekeeping gene (HKG): 2
2DCt=2
2Ct(sample)/2
2Ct(HKG).
Finally, in order to compare the data from different experimental
conditions, we calculated 2
2DDCt values, which are obtained by
normalizing the experimental data by reference data. For
example, data from treated cells are normalized to untreated
cells, according to the formula: 2
2DDCt=2
2DCt(treated cells)/
2
2DCt(untreated cells). Differentially expressed genes were defined
as those that changed by .2-fold. Java TreeView was used to
represent data as heat map representations [42].
Phylogenetic analysis of human TRIM proteins
The amino-acid sequences of all human TRIM proteins were
obtained from the ‘‘HUGO Gene Nomenclature Committee at the
European Bioinformatics Institute’’ (http://www.genenames.org). A
Human TRIM Gene Expression
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pbil.univ-lyon1.fr/software/njplot.html), on the basis of a
ClustalX2 sequence alignment of all TRIM proteins deleted
from their Ct domain(s) (http://www.clustal.org/), with a
bootstrap trial of 1000. TRIM alignments are available from
the authors by request.
Table 1. Genes screened in the PCR array analysis.
TRIM Official Accession No. Amplicon Amplicon TRIM Official Accession No. Amplicon Amplicon
symbol (Genbank) size (bp) position symbol (Genbank) size (bp) position
1 MID2 NM_012216 155 2150–2168 45 NM_025188 123 2311–2331
2 NM_015271 51 3325–3344 46 NM_025058 158 2184–2202
3 NM_006458 130 2032–2053 47 NM_033452 175 1304–1326
4 NM_033017 134 3081–3102 48 NM_024114 89 140–161
5 NM_033093 111 924–943 49 NM_020358 107 1245–1267
6 NM_058166 181 1035–1054 50 NM_178125 137 1197–1215
7 NM_033342 159 767–787 51 SPRYD5 NM_032681 191 605–625
8 NM_030912 111 1450–1468 52 NM_032765 191 312–332
9 NM_015163 93 1958–1976 53 XR_016180 181 1052–1071
10 NM_006778 181 785–807 54 NM_187841 161 752–771
11 NM_145214 158 1279–1299 55 NM_184087 85 662–681
13 NM_005798 158 389–411 56 NM_030961 158 459–477
14 NM_014788 140 559–577 58 NM_015431 172 948–966
15 NM_033229 100 2024–2048 59 NM_173084 114 541–561
16 NM_006470 148 1004–1022 60 NM_152620 113 266–284
16L NM_001037330 125 20–43 61 NM_001012414 176 431–453
17 NM_016102 153 1216–1234 62 NM_018207 94 1177–1197
18 MID1 NM_000381 139 2214–2232 63 NM_032588 100 1567–1588
19 PML NM_033238 67 1328–1348 64 XM_061890 191 1213–1233
20 MEFV NM_000243 165 1906–1924 65 NM_173547 141 2870–2888
21 NM_003141 173 1137–1159 66 XM_084529 88 6581–6601
22 NM_006074 139 2293–2313 67 NM_001004342 185 8275–8296
23 NM_001656 143 3551–3574 68 NM_018073 180 1322–1341
24 NM_003852 191 2560–2581 69 NM_182985 99 1409–1431
25 NM_005082 161 965–985 71 NM_001039111 171 2061–2079
26 NM_003449 154 1576–1595 72 NM_001008274 132 1504–1522
27 NM_006510 164 2735–2754 73 NM_198924 121 1195–1219
28 NM_005762 131 1737–1755 74 NM_198853 123 321–341
29 NM_012101 84 2833–2851 L1 NM_178556 173 1138–1157
30 NM_007028 166 1723–1743 PPIA NM_021130 191 838–861
32 NM_012210 179 326–345 STAT1 NM_007315 92 199–221
33 NM_015906 132 3370–3391 EIF2AK2 NM_002759 84 1395–1415
34 NM_021616 134 849–868 HIST4H4 NM_175054 92 120–141
35 NM_171982 190 421–439 OAS2 NM_002535 139 345–363
36 NM_018700 165 482–501 MX1 NM_002462 184 1883–1905
37 NM_015294 94 2883–2902 ADAR NM_001111 150 3896–3918
38 NM_006355 172 1486–1505 APOBEC3G NM_021822 156 1103–1124
39 NM_021253 131 1628–1649 APOBEC3F NM_145298 89 4610–4630
40 NM_138700 105 398–418 CSF1 NM_000757 181 523–545
41 NM_201627 181 868–889 HPRT1 NM_000194 89 974–993
42 NM_152616 101 2371–2391 RPL13A NM_012423 90 940–960
43 NM_138800 157 1156–1176 GAPDH NM_002046 175 1287–1310
44 NM_017583 120 1097–1119 ACTB NM_001101 191 1202–1222
doi:10.1371/journal.pone.0004894.t001
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Promoter analysis was carried out using the PROMO virtual
laboratory (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/
promoinit.cgi?dirDB=TF_8.3) and Genomatix MatInspector
(http://www.genomatix.de/products/MatInspector/) programs
for identifying putative transcription factor binding sites
[43,44,45]. Briefly, 1 kb of DNA upstream of the predicted
transcription start site for each TRIM protein along with 100 bp
reading into the mRNA (21000 bp to +100 bp) was selected from
the human genome for analysis. These sequences were analyzed in
PROMO and MatInspector using versions 8.3 and 7.1 of the
TRANSFAC matrix library respectively. For PROMO, hits were
scored for specific transcription factors based on dissimilarity
values of less than 0.1 and random expectation values of less than
0.01. For MatInspector, hits were scored on matrix similarities
above 0.8. Genomic positive controls consisting of promoter
regions known to possess binding sites for each selected
transcription factor were used to evaluate the stringency of the
PROMO and MatInspector algorithms to determine significant
results (STAT1, OAS2, MX1, APOBEC3G, etc). Negative
controls consisting of housekeeping genes (GAPDH, ACTB) and
randomized DNA sequences were used to evaluate and eliminate
less stringent matrices.
Results
In order to perform a comprehensive study of TRIM gene
expression in human primary lymphocytes and macrophages,
unstimulated peripheral blood lymphocytes (PBL) and monocyte
derived macrophages (MDM) from 3 donors were either left
untreated or stimulated with type I IFN, type II IFN or immune
complexes (IC, in the case of MDM only), as indicated in the
Materials and Methods section. After RNA extraction and cDNA
preparation, we screened 86 gene transcripts by real-time
quantitative PCR. In addition to the 72 TRIM gene transcripts,
we also analyzed the expression of a number of housekeeping
genes to standardize the assays, such as PPIA (peptidylprolyl
isomerase A, cyclophilin A), HPRT1 (hypoxanthine phosphor-
ibosyltransferase 1), RPL13A (ribosomal protein L13a), GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) and ACTB (actin
beta) (Table 1). We also included some genes whose expression is
known to be either down-regulated by IFN, such as HIST4H4
(histone cluster 4, H4) or up-regulated, such as STAT1 (signal
transducer and activator of transcription 1, 91kDa), EIF2AK2
(Homo sapiens eukaryotic translation initiation factor 2-alpha
kinase 2, PKR), OAS2 (29-59-oligoadenylate synthetase 2, 69/
71 kDa), MX1 (myxovirus resistance 1), ADAR (adenosine
deaminase, RNA-specific), APOBEC3G and APOBEC3F (apoli-
poprotein B mRNA editing enzyme, catalytic polypeptide-like 3G
and 3F) (Table 1) [32,46]. Furthermore, we analyzed CSF1 (or M-
CSF, Macrophage colony-stimulating factor 1) expression as a
control for IC-mediated MDM activation, since we have
previously shown that CSF1 expression is up-regulated following
FccR cross-linking [39]. Finally, we included internal controls to
account for genomic DNA contamination, reverse transcription
efficiency and PCR efficiency, in order to validate the screen and
allow proper comparison between experiments. All data were
analyzed using the 2
2DDCt method. From the collected data, we
first analyzed the basal expression of the screened genes in
untreated MDM and PBL. In order to compare the basal
expression of each gene in lymphocytes and MDM, we normalized
our values by a housekeeping gene whose expression is as similar
as possible in both cell types. Toward this end, we compared the
mean Ct values for each housekeeping gene in untreated MDM
and PBL. As shown in Figure 2A, RPL13A presents the smallest
standard deviation values among the 5 selected housekeeping
genes, demonstrating that its expression was almost identical in
PBL and MDM. Therefore, we used RPL13A to compare TRIM
gene expression between both cell types.
Figures 2B and 2C compare absolute (2B) or relative (2C)
TRIM gene expression in human MDM and lymphocytes. Among
the 72 analyzed TRIM transcripts, 27 were not detectable in
either MDM or PBL (TRIM6, 10, 15, 17, 18/MID1, 29, 31, 35,
36, 42, 43, 45, 46, 48, 49, 50, 51/SPRYD5, 53, 55, 60, 61, 63, 64,
67, 72, 74 and L1) (Figure 2B). Some were specifically expressed in
MDM (TRIM7, 9, 40 and 54) or in PBL (TRIM20/MEFV, 23, 71
and 73) (Figures 2B and 2C).
Next, we analyzed which genes are regulated by IFN in both
cell types and by IC in MDM. As described above, we first
determined the housekeeping gene that had the most stable
expression in a given cell type upon IFN or IC treatment in order
to normalize our results. Mean Ct values of the 5 screened
housekeeping genes in untreated and treated cells with either type
I or type II IFN (as well as IC in the case of MDM) were
calculated, along with the corresponding standard deviation values
(Figure 3A). Actin B (ACTB) expression was found to be almost
identical in untreated and IFN-treated PBL and also in untreated,
IFN- or IC-treated MDM and was thus selected as the most
suitable gene to normalize our results in both cell types.
The regulation of each TRIM gene after normalization to
ACTB expression is shown in Figure 3B. We considered gene
expression variations as significant when we observed a .2-fold
variation compared to untreated cells. Genes that were signifi-
cantly up- or down-regulated are represented in red and green in
the heat map representation, respectively (Figure 3B). As expected,
we found that STAT1, EIF2AK2, OAS2, MX1, ADAR,
APOBEC3G and APOBEC3F were significantly up-regulated by
both type I and type II IFN [32], and that TLR4 expression was
up-regulated by type I IFN in MDM [46], whereas HIST4H4
expression was down-regulated upon IFN-treatment [32]. In
MDM, type I IFN up-regulated the expression of 16 TRIM genes
(TRIM5, 6, 14, 19/PML, 20/MEFV, 21, 22, 25, 26, 31, 34, 35,
38, 56, 58 and 69) and down-regulated the expression of 5
(TRIM28, 37, 54, 59 and 66). Among these TRIM genes, type II
IFN only induced the up-regulation of 7 genes (TRIM19/PML,
20/MEFV, 21, 22, 25, 56 and 69) but induced the down-
regulation of 11 (TRIM2, 4, 9, 16, 16L, 28, 32, 37, 54, 59 and 66).
In PBL, 14 TRIM genes were up-regulated by type I IFN
(TRIM5, 6, 14, 19/PML, 20/MEFV, 21, 22, 25, 26, 31, 34, 35,
38 and 56) and 7 by type II IFN (TRIM19/PML, 20/MEFV, 21,
22, 26, 56 and 69) (Figure 3B). The only gene whose expression
was significantly down-regulated in PBL following IFN treatment
was TRIM16L (Figure 3B). Interestingly, whereas TRIM6,
TRIM31 and TRIM35 transcripts were undetectable in either
untreated MDM or PBL, they could be detected in type I IFN-
treated cells. The expression of TRIM9 in PBL was also weakly
induced by type II IFN. Similarly, both type I and type II IFN
induced the expression of TRIM20/MEFV in MDM, which was
not detectable in unstimulated cells.
As expected, the expression pattern of TRIM genes following
IC-stimulation and activation of MDM through FccR was
completely different from what was observed with IFN. First of
all, none of the IFN-induced positive controls were up-regulated.
On the contrary, STAT1, OAS2 and APOBEC3F expression was
found to be down-regulated by more than 2-fold. As expected, the
expression of CSF1 was highly up-regulated in IC-stimulated
MDM. Regarding TRIM genes, only 2 were significantly up-
regulated: TRIM9 (3.9 fold) and TRIM54 (3.4 fold), whereas 8 of
Human TRIM Gene Expression
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66).
Quantitative data on the regulation of TRIM genes whose
expression was significantly affected by type I or type II IFN in
PBL or MDM or by IC in MDM is represented in Figure 4. It
must be noted that IFN-treated MDM and PBL gave overall
similar profiles, but variations of gene expression were usually
more pronounced in MDM. This probably reflects their higher
sensitivity to IFN. Among the 16 TRIM genes up-regulated by
type I IFN, only TRIM5, TRIM19/PML and TRIM22 showed a
.10-fold induction in MDM. TRIM genes were less susceptible to
type II IFN, since only TRIM19/PML, TRIM22 and TRIM25
were up-regulated approximately 5-fold and MEFV/TRIM20 18-
fold. TRIM54 was significantly down-regulated both by type I and
type II IFN, 6 and 10-fold, respectively, as opposed to its up-
regulation in IC-stimulated MDM.
Discussion
Our screen revealed that, 45 out of the 72 human TRIM genes
show detectable ex vivo expression in blood lymphocytes or
unstimulated MDM. Upon type I IFN treatment, 3 additional
TRIM transcripts can be detected in both cell types. Twenty seven
human TRIM genes were found to be sensitive to IFN treatment,
among which 16 were up-regulated by type I IFN and 8 by type II
IFN.
Interestingly, our data partially overlap with a recent study
performed on mouse TRIM genes [35] (Figure 5). For instance,
TRIM6, 14, 19/PML, 20/MEFV, 21, 25, 26 and 34 were up-
regulated in response to IFNs in our study and classified to cluster
2 or 3 by Rajsbaum et al. These two clusters comprise TRIM
genes found to be highly expressed in macrophages and dendritic
cells (DC) and whose expression is further induced following
influenza virus infection in an IFN-dependent manner [35]. We
also identified human TRIM5, 22, 31, 38, 56, 58 or 69 as
additional genes induced by type I IFN, but these genes were not
analyzed or have no homologue in mouse [35]. Our two studies
also show that both constitutive expression and IFN-inducibility of
TRIM genes are cell type dependent, which may have an impact
on the antiviral properties of individual TRIM family members
[35]. Our data also largely confirm a gene expression study
performed by Martinez and colleagues [47] and re-analyzed by
Rajsbaum et al. in order to examine TRIM gene expression in
human macrophages stimulated with IFN-c and LPS [35]. Despite
different experimental conditions, a good overall agreement can
be observed (Figure 5). The main discrepancies concern a number
of TRIM genes (including TRIM2, 3, 10, 13, 17, 18, 29, 45, 46, 48
and 62) which were found to be up-regulated by IFN-c/LPS
treatment by Martinez et al., although they did not respond to
IFNs in our study. It has to be noted that the study by Martinez et
al. was performed on M-CSF-treated MDM, further activated for
18 h with LPS and IFN-c [47]. In contrast, we avoided the use of
exogenous cytokines, such as M-CSF, for differentiating mono-
cytes into macrophages, since it may directly induce the expression
of several genes [48,49] and even influence retroviral replication
[50]. In addition, we identified TRIM20/MEFV as being highly
up-regulated by both type I and type II IFN, in accordance with
another study [26], whereas Martinez et al. did not [35].
Interestingly, our analysis revealed that TRIM genes are more
sensitive to type I IFN, which is considered as the ‘‘antiviral IFN’’,
than to type II IFN. Up-regulation of TRIM genes by type I IFN
may indicate the presence of interferon-stimulation response
elements (ISREs) or closely related interferon regulatory factor
elements (IRFEs) in the genomic regions upstream of TRIM genes
that serve as docking sites for interferon regulatory factors (IRFs)
involved in IFN gene regulation. Briefly, of the nine known
mammalian IRFs, IRF-1 and IRF-2 have been extensively studied
and are known to bind IRFE sequences (consensus:
G(A)AAA
G/C
T/CGAAA
G/C
T/C) to activate or inactivate gene
expression following type I or II IFN stimulation [51]. IRF3 and
IRF7 bind ISRE sequences (consensus:
A/GNGAAANN-
GAAACT) [52] to activate gene expression; this has been most
notably demonstrated for the IFN-b enhanceosome [53]. To look
for regulatory elements that respond to type I IFN, we carried out
an in silico analysis and identified putative ISREs and IRFEs within
the upstream regions of several IFN-induced TRIM genes with
matrix similarities exceeding 95% (Figure 5, and Table S1 with
exact sequence and positions). We chose to focus on ISREs and
IRFEs primarily because of their readily identifiable and
conserved consensus sequences as well as their preference for
type I IFN stimulated transcription factors. While our findings are
no substitute for direct functional data on TRIM gene promoters,
the correlation with the IFN stimulated up-regulation of TRIM
genes is striking and provides a sound basis for future work on the
mechanisms of TRIM gene regulation.
There appears to be no correlation between the susceptibility to
IFNs and the domain structure. Indeed, TRIM5, 6, 21, 22, 25, 26,
34, 35, 38, 58 and 69 present the RBCC/B30.2 structure
characteristic of the C-IV TRIM subfamily, according to the
Short and Cox classification [54] (Figure 1), whereas TRIM19/
PML, TRIM31 and 56 belong to the C-V subfamily and TRIM14
and TRIM20/MEFV have not been sub-classified, since they lack
the RING domain [54] (Figure 1). As shown in Figure 6, TRIM
genes whose expression is up-regulated by type I IFN are dispersed
throughout the phylogenetic tree of human TRIM genes. The
only correlation concerns the TRIM genes localized in the
11p15.4 cluster, which comprise TRIM5, 6, 22 and 34, all of them
being up-regulated by IFNs (Figure 6), an observation that has also
been reported in murine cells [35]. Two other IFN-induced TRIM
genes, TRIM26 (induced by both type I and II IFNs) and
TRIM31 (only induced by type I IFN) are located within another
major cluster of TRIM encoding genes (containing TRIM10, 15,
26, 31, 39 and 40) located in the major histocompatibility complex
region on chromosome 6, at 6p21.33 [55].
Whether induction of gene expression systematically correlates
with an increased protein expression will require further studies.
Although this is likely, such a correlation may be complicated by
the fact that most TRIM genes, if not all, encode several protein
Figure 2. TRIM gene expression in human primary macrophages and lymphocytes. cDNA was prepared from primary macrophages (MDM)
and lymphocytes (PBL) from 3 donors, as described in the Materials and Methods section. The expression of 86 genes, including 72 TRIM genes and 5
housekeeping genes, was analyzed by quantitative RT-PCR array. A. Comparison of the expression of 5 housekeeping genes in untreated MDM and
PBL. The mean Ct values for each gene in untreated cells from 3 donors are shown. Error bars show standard deviation. RPL13A presented the
smallest standard deviation values and was therefore selected for normalization. B. Constitutive expression of TRIM genes in MDM (M) and PBL (P).
Histograms represent mean 2
2DCt values for each gene6SD. C. Relative expression of TRIM genes in MDM (M) and PBL (P). Mean 2
2DCt values were
determined by subtracting RPL13A, and each sample was normalized to the median expression of each gene in both cell types. Resulting 2
2DDCt
values were represented as a heat map, using Java TreeView. Green: low relative expression; Yellow: median value (same expression in MDM and
PBL); Red: high relative expression.
doi:10.1371/journal.pone.0004894.g002
Human TRIM Gene Expression
PLoS ONE | www.plosone.org 7 March 2009 | Volume 4 | Issue 3 | e4894Human TRIM Gene Expression
PLoS ONE | www.plosone.org 8 March 2009 | Volume 4 | Issue 3 | e4894Figure 4. TRIM genes whose expression is regulated by IFN or immune complex. These diagrams show the TRIM genes whose expression
is either up- (.2-fold increase compared to untreated cells) or down-regulated (.2-fold decrease compared to untreated cells) by type I IFN, type II
IFN or Immune complex (IC). The effect of each treatment on the expression of non-TRIM genes included in the screen is also shown. Data are
represented as fold induction.
doi:10.1371/journal.pone.0004894.g004
Figure 3. TRIM gene expression in response to IFN or immune complex. Primary macrophages (MDM) or lymphocytes (PBL) from 3 donors
were left untreated or were treated with type I IFN, type II IFN or preformed immune complexes (IC, in the case of MDM only), as described in the
Materials and Methods section. The expression of 86 genes, including 72 TRIM genes and 5 housekeeping genes, was analyzed by PCR array. A.
Selection of a housekeeping gene to normalize the expression of TRIM genes in untreated Vs IFN- or IC-treated cells. The diagram shows the mean
expression of 5 housekeeping genes in untreated and treated MDM (squares) or PBL (triangles). The mean Ct values for each gene in untreated cells
and IFN or IC-treated cells from 3 donors are shown. Error bars show standard deviation. ACTB presented the smallest standard deviation values and
was therefore selected for normalization. B. Induction of TRIM genes in primary cells treated with type I IFN (I), type II IFN (II) or IC. Mean 2
2Ct values
for each gene in cells from 3 donors were normalized to ACTB expression to calculate 2
2DCt values. Normalization to the mean expression of each
gene in untreated cells gave the 2
2DDCt values, which were presented as a heat map using Java TreeView. Green: Down-regulation of gene
expression; Yellow: No change; Red: Up-regulation of gene expression. A significant modification of gene expression was defined as a .2 down- (dark
green) or up-regulation (dark red).
doi:10.1371/journal.pone.0004894.g003
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stability. Thus, a study on TRIM protein expression would require
TRIM isoform-specific antibodies directed against all known
members. In consequence, induction by IFNs has been demon-
strated at the protein level in the case of very few TRIMs,
including TRIM5 [20], TRIM8 [56] and TRIM19/PML [23,24].
Interestingly, among the 16 TRIM genes we found to be IFN-
induced, 10 of them have previously been reported to have an
antiviral activity or are involved in processes associated with innate
immunity, including TRIM5 [20,21,22], TRIM19/PML
[23,24,25], TRIM20/MEFV [26], TRIM21 [27,28], TRIM22
[9,10], TRIM25 [15], TRIM26 [14], TRIM31 [14], TRIM34
[57] and TRIM56 [14]. This observation re-emphasizes the link
between IFN-regulation of gene expression and antiviral activity
and further suggests a role in antiviral defence for the 6 additional
proteins we identified as IFN-inducible (TRIM 6, 14, 35, 38, 58
and 69). Very little is known about these 6 TRIM proteins, apart
the fact that TRIM6 can block HIV-1 when its RBCC motif is
artificially fused to the B30.2 domain from rhesus macaque
TRIM5a [58].
It has to be noted that, although IFN triggers an antiviral
response and up-regulates the expression of many TRIM genes,
IFN-inducibility is not an absolute prerequisite for displaying
antiviral function. Indeed, several TRIM proteins which have
been previously involved in innate immunity, such as TRIM1/
MID2 [8], TRIM11 [14], TRIM28 [12] or TRIM62 [14], were
not found to be induced by IFN. Thus, antiviral TRIM proteins
may also be expressed constitutively or be induced through other
stimuli, as illustrated by the case of TRIM20 and TRIM35, which
were found to be up-regulated following influenza virus infection
in murine macrophages and dendritic cells independently of type I
IFN receptor expression [35], suggesting the existence of IFN-
independent regulation(s) of TRIM expression. In parallel to IFN
stimulation, we also investigated the effects of FccR aggregation by
Figure 5. Summary of TRIM expression in mouse and human macrophages upon various stimuli and in silico promoter analysis.
TRIM expression in human macrophages upon IFN treatment. This part of the table shows the comparison of TRIM gene expression in mouse
macrophages treated with LPS or poly(I:C) [35], in human macrophages upon IFN-c and LPS treatment [35,47], and in human macrophages
stimulated with either type I or type II (c) IFN (our study). In silico promoter analysis. Table illustrating potential transcription factor binding sites
based on sequence analysis of 1 kb of genomic DNA upstream of each TRIM protein. IRF sites were scored using the PROMO virtual laboratory using
matrices specific to selected human transcription factors (TFs). Highest scoring TF binding sites (+++) had dissimilarity values of less than 0.1 and
random expectation values (noted RE within the table key) of less than 0.01. Calculated sites meeting only one of the above criteria (++) or neither (+)
are indicated. ISRE/IRF sites were further corroborated with MatInspector. Highest scoring TF binding sites (+++) had similarity values above 0.9, (++)
values between 0.85–0.89, and (+) values between 0.80–0.84. Numerous positive genomic controls (OAS2, MX1, STAT1, APOBEC3G, APOBEC3F, etc.)
and their calculated TF profiles were used to evaluate the stringency of hits. Negative genomic controls GAPDH and ACTB were used to evaluate the
stringency of the programs.
doi:10.1371/journal.pone.0004894.g005
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that IC-stimulation of MDM via the activating FccR induces the
restriction of HIV-1 and related primate lentiviruses after entry
[40]. The potential involvement of members of the TRIM family
in the restriction should be considered. We were also interested in
analyzing the effect of signaling pathways, such as those triggered
Figure 6. Phylogenetic tree of human TRIM proteins. This joining-neighbor-tree of human TRIM proteins deleted from their Ct domain(s) was
constructed using the CLUSTALW and NJplot programs. Numbers indicate bootstrap proportions after 1000 replications. The scale bar represents
0.05 substitutions per amino acid position. Red boxes show TRIM genes which are up-regulated by type I IFN in macrophages, whereas blue boxes
show TRIM genes which are up-regulated following activation of MDM with immune complex (IC). TRIM genes belonging to the 11p15.4 cluster are
indicated.
doi:10.1371/journal.pone.0004894.g006
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induced Jak-STAT signaling [59], on TRIM gene expression.
Interestingly enough, FccR cross-linking-induced modulation
produced a mirror image of IFN induced modulation, down-
regulating several TRIM genes induced by IFNs, and up-
regulating other genes such as TRIM9 or TRIM54 which were
unaffected or highly down-regulated by IFNs, respectively. These
last two genes encode TRIM proteins containing a COS box [54],
which has been described as a microtubule binding motif [54].
TRIM9 and TRIM54 are only expressed in MDM in the absence
of treatment and not in PBL where their expression can only be
detected following type II IFN treatment. In mouse primary cells
on the contrary, TRIM9 was found to be highly expressed in T-
cells but less so or not at all in macrophages and DC [35]. Up-
regulation of these two proteins might be related to the MTOC
rearrangement in macrophages which is associated to FccR-
triggered phagocytosis [60]. Whether these genes are involved in
the induction of an anti-retroviral response in FccR-activated
macrophages warrants further studies.
In conclusion, our study revealed expression modulation of
several TRIM genes by two different signaling pathways involved
in triggering antiviral responses. Some of these TRIM members
have not been previously described as being affected by either
IFNs or FccR engagement. Our results suggest a potential
implication of these TRIM proteins in antiviral activities mediated
by these stimuli in lymphocytes and MDM. Further functional
studies are needed to address this hypothesis.
Supporting Information
Table S1 In silico identification of IRF binding sites and ISRE
within human TRIM gene promoters. Raw data sets for IRF
binding sites and ISRE for both PROMO and MatInspector.
Numbering is based on the transcription start site at position 1000.
PROMO displays TRIMs and potential IRFs as indicated, along
with calculated start and end positions of transcription factor (TF)
binding sites. Dissimilarity values give the percent difference in
sequence similarity between the input TRIM sequence and the
calculated TF consensus matrix. RE, or random expectation,
yields the probability that the TF consensus binding sequence
would occur by chance, where 0.1 denotes 1 occurrence in every
10‘4 bases. MatInspector displays TRIMs, potential IRFs, start
and end positions, as well as core and matrix similarities as
indicated. Sequences for potential binding sites are shown from
both programs.
Found at: doi:10.1371/journal.pone.0004894.s001 (0.04 MB
XLS)
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